Abstract:Background Oncolytic viruses are considered part of immunotherapy and have shown promise in preclinical experiments and clinical trials. Results from these studies have suggested that tumor microenvironment remodeling is required to achieve an effective response in solid tumors. Here, we assess the extent to which targeting specific mechanisms underlying the immunosuppressive tumor microenvironment optimizes viroimmunotherapy. Methods We used RNA-seq analyses to analyze the transcriptome, and validated the results using Q-PCR, flow cytometry, and immunofluorescence. Viral activity was analyzed by replication assays and viral titration. Kyn and Trp metabolite levels were quantified using liquid chromatography–mass spectrometry. Aryl hydrocarbon receptor (AhR) activation was analyzed by examination of promoter activity. Therapeutic efficacy was assessed by tumor histopathology and survival in syngeneic murine models of gliomas, including Indoleamine 2,3-dioxygenase (IDO)-/- mice. Flow cytometry was used for immunophenotyping and quantification of cell populations. Immune activation was examined in co-cultures of immune and cancer cells. T-cell depletion was used to identify the role played by specific cell populations. Rechallenge experiments were performed to identify the development of anti-tumor memory. Results Bulk RNA-seq analyses showed the activation of the immunosuppressive IDO-kynurenine-AhR circuitry in response to Delta-24-RGDOX infection of tumors. To overcome the effect of this pivotal pathway, we combined Delta-24-RGDOX with clinically relevant IDO inhibitors. The combination therapy increased the frequency of CD8 + T cells and decreased the rate of myeloid-derived suppressor cell and immunosupressive Treg tumor populations in animal models of solid tumors. Functional studies demonstrated that IDO-blockade-dependent activation of immune cells against tumor antigens could be reversed by the oncometabolite kynurenine. The concurrent targeting of the effectors and suppressors of the tumor immune landscape significantly prolonged the survival in animal models of orthotopic gliomas. Conclusions Our data identified for the first time the in vivo role of IDO-dependent immunosuppressive pathways in the resistance of solid tumors to oncolytic adenoviruses. Specifically, the IDO-Kyn-AhR activity was responsible for the resurface of local immunosuppression and resistance to therapy, which was ablated through IDO inhibition. Our data indicate that combined molecular and immune therapy may improve outcomes in human gliomas and other cancers treated with virotherapy.

Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy

Cutting both ways: the innate immune response to oncolytic virotherapy

Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

Oncolytic Viruses in Cancer Immunotherapy

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

Immune landscape and response to oncolytic virus-based immunotherapy

Oncolytic virotherapy: basic principles, recent advances and future directions

Current Landscape and Perspective of Oncolytic Viruses and Their Combination Therapies.

Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

The investigation of oncolytic viruses in the field of cancer therapy

Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

Virus-Based Immuno-Oncology Models

Tuning Cellular Metabolism for Cancer Virotherapy

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy

Personalizing Oncolytic Immunovirotherapy Approaches

Therapeutic potential of oncolytic viruses in the era of precision oncology